Novel multi-specific antibody programs advancing from discovery through clinical development across immunology and oncology.
Multi-specific antibodies for B cell-mediated autoimmune and inflammatory diseases.
Trispecific antibodies designed to redirect the immune system against solid tumors and hematological malignancies.
Programs advancing in collaboration with our strategic partners.
We welcome discussions with pharmaceutical partners and investors about our pipeline programs.
Contact us